Home Faculty Accreditation View Program Accreditation Exired Contact

Optimizing Outcomes for Patients With Metabolic Bone Disease

(Accreditation Expired)

References

  1. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int. 2004;15:767-778.
  2. Simonelli C, Killeen K, Mehle S, Swanson L. Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc. 2002;77:334-338.
  3. Andrade SE, Majumdar SR, Chan KA, et al. Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med. 2003;163:2052-2057.
  4. Siris ES, Bilezikian JP, Rubin MR, et al. Pins and plaster aren't enough: a call for the evaluation and treatment of patients with osteoporotic fractures. J Clin Endocrinol Metab. 2003;88:3482-3486.
  5. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int. 2003;14:965-968.
  6. Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH. Assessment of adherence and persistence with daily and weekly dosing regimens of oral bisphosphonates. Osteoporos Int. 2004;15(suppl 2):S52.
  7. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271-287.
  8. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.
  9. Caro JJ, Ishak KJ, Huybrechts KF, et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 2004;15:1003-1008.
  10. Eastell R, Garnero P, Vrijens B, et al. Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the Impact study. Presented at: 30th European Symposium on Calcified Tissues; May 8-12, 2003; Rome, Italy.
  11. Cramer JA, Amonkar MM, Hebborn A, Suppapanya N. Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women? Poster presented at: 26th Annual Meeting of the American Society for Bone and Mineral Research; October 1-5, 2004; Seattle, Wash.
  12. Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123.
  13. Jaret P. Ten ways to improve patient compliance. Hippocrates. 2001;15(2).
  14. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60:657-665.
  15. Ettinger M, Gallagher R, Amonkar M, et al. Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate. Arthritis Rheum. 2004;50(suppl):S513-S514.
  16. Caro JJ, Ishak KJ, Huybrechts KF, et al. Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int. 2003;14(suppl 7):S2-S3.
  17. Ettinger B, Pressman A, Schein J, et al. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm. 1998;4:488-492.
  18. Chapurlat RD. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis. Treat Endocrinol. 2005;4:115-125.
  19. Feldstein AC, Elmer PJ, Smith DH, et al. Results of a randomized, controlled trial to improve the management of osteoporosis after fracture. J Bone Miner Res. 2003;18(suppl 2):S268.
  20. Altman RD. Paget's disease of bone. In: Coe FL, Favus MJ, eds. Disorders of Bone and Mineral Metabolism. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:985-1020.
  21. Daroszewska A, Ralston SH. Genetics of Paget's disease of bone. Clin Sci (Lond). 2005;109:257-263.
  22. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002;70:1582-1588.
  23. Watts GDJ, Wymer J, Kovach MJ, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet. 2004;36:377-381.
  24. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and nonpagetic bone tissue. Arthritis Rheum. 1980;23:1095-1103.
  25. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res. 2001;16:1379-1387.
  26. Meunier PJ, Salson C, Mathieu L, et al. Skeletal distribution and biochemical parameters of Paget's disease. Clin Orthop Relat Res. April 1987:37-44.
  27. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558-566.
  28. Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 1995;38:851-858.
  29. Siris E, Weinstein RS, Altman R, et al. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 1996;81:961-967.
  30. Miller PD, Brown JP, Siris ES, et al, for the Paget's Risedronate/Etidronate Study Group. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med. 1999;106:513-520.
  31. Chakravarty K, Merry P, Scott DGI. A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone. J Rheumatol. 1994;21:2118-2121.
  32. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.
  33. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2005;Jul 19; [Epub ahead of print].
  34. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908.
  35. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science. 1969;165:1262-1264.
  36. Schenk R, Merz WA, Mühlbauer R, et al. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 1973;11:196-214.
  37. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751.
  38. Gasser JA, Green JR. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone. 2002;30(suppl):41S.
  39. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
  40. Bone HG, Hosking D, Devogelaer J-P, et al, for the Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199.
  41. Watts N, McClung M, Olszynski W, et al. Effects of risedronate discontinuation on bone turnover and bone mineral density in postmenopausal women with osteoporosis. Presented at: The International Society for Clinical Densitometry; January 28-31, 2004; New Orleans, La. Available at: www.iscd.org/Visitors/conferences/index.cfm.
  42. Lawson MA, Triffitt JT, Ebetino FH, et al. Potential bone mineral binding differences among bisphosphonates can be demonstrated by the use of hydroxyapatite column chromatography. J Bone Miner Res. 2005;20(suppl 1):S396.






Printer settings may vary. Please use landscape layout option.




Copyright © 2006 Medical Education Resources, Inc. All rights reserved.